RT Journal Article
SR Electronic
T1 Patterns of peritoneal dissemination and response to systemic chemotherapy in common and rare peritoneal tumors treated by cytoreductive surgery: Study protocol of a prospective, multi-center, observational study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.01.21254760
DO 10.1101/2021.04.01.21254760
A1 Bhatt, Aditi
A1 Rousset, Pascal
A1 Baratti, Dario
A1 Biacchi, Daniele
A1 Benzerdjeb, Nazim
A1 Hingh, Ignace de
A1 Deraco, Marcello
A1 Gushcin, Vadim
A1 Kammar, Praveen
A1 Labow, Daniel
A1 Levine, Edward
A1 Moran, Brendan
A1 Mohamed, Faheez
A1 Morris, David
A1 Mehta, Sanket
A1 Nissan, Aviram
A1 Alyami, Mohammad
A1 Adileh, Mohammad
A1 Barat, Shoma
A1 Yacov, Almog Ben
A1 Campbell, Kurtis
A1 Cummins-Perry, Kathleen
A1 Cortes-Guiral, Delia
A1 Cohen, Noah
A1 Parikh, Loma
A1 Alammari, Samer
A1 Bashanfer, Galal
A1 Alshukami, Anwar
A1 Kundalia, Kaushal
A1 Goswami, Gaurav
A1 Van de Vlasakker, Vincent
A1 Sittig, Michelle
A1 Sammartino, Paolo
A1 Sardi, Armando
A1 Villeneuve, Laurent
A1 Turaga, Kiran
A1 Yonemura, Yutaka
A1 Glehen, Olivier
YR 2021
UL http://medrxiv.org/content/early/2021/04/07/2021.04.01.21254760.abstract
AB Introduction Despite optimal patient selection and surgical effort, recurrence is seen in over 70% of patients undergoing cytoreductive surgery(CRS) for peritoneal metastases (PM). Apart from the peritoneal cancer index(PCI), completeness of cytoreduction and tumor grade, there are other factors like disease distribution in the peritoneal cavity, pathological response to systemic chemotherapy(SC), lymph node metastases and morphology of PM which may have prognostic value. One reason for the underutilization of these factors is that they are known only after surgery. Identifying clinical predictors, specifically radiological predictors, could lead to better utilization of these factors in clinical decision making and the extent of peritoneal resection performed for different tumors. This study aims to study these factors, their impact on survival and identify clinical and radiological predictors. Methods and analysis There is no therapeutic intervention in the study. All patients with biopsy proven PM from colorectal, appendiceal, gastric and ovarian cancer and peritoneal mesothelioma undergoing CRS will be included. The demographic, clinical, radiological, surgical and pathological details will be collected according to a pre-specified format that includes details regarding distribution of disease, morphology of PM, regional node involvement and pathological response to SC. In addition to the absolute value of PCI, the structures bearing the largest tumor nodules and a description of the morphology in each region will be recorded. A correlation between the surgical, radiological and pathological findings will be performed and the impact of these potential prognostic factors on progression-free and overall survival determined. The practices pertaining to radiological and pathological reporting at different centers will be studied. Ethics and dissemination The study protocol has been approved by the Zydus Hospital ethics committee (27th July, 2020) and Lyon-sud ethics committee (A15-128). It is registered with the clinical trials registry of India (CTRI/2020/09/027709).The results will be published in peer-reviewed scientific journals.Strength and limitationsA prospective correlation between the radiological, surgical and pathological findings in patients undergoing CRS will be performed which has not been done before.Being prospective in nature it will also enable us to evaluate the impact of the current treatment practices on the clinical end-pointsThere is fixed protocol for radiological and pathological evaluation for which there are no specific guidelinesThe data collection format will capture all the relevant data but this may affect compliance.Despite the large sample size planned for each primary site, the heterogeneity of treatment protocols may be a limiting factor while evaluating the impact on survival.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialCTRI/2020/09/027709Funding StatementThe authors received no funding for this studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol has been approved by the Zydus Hospital ethics committee (27th July, 2020) and Lyon-sud ethics committee (A15-128).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesStudy protocol- not applicable